

B I B L I O G R A P H Y

1. Bjorck S, Devlin K, Herlitz H, Larsson O, Aurell M.
Renin secretion in advanced diabetic nephropathy.
Scand J Urol Nephrol 1984; 79 (Suppl) : 53-7.
2. Bjorck S, Mulec H, Johnsen SA, Nyberg G, Aurell M.
Contrasting effects of enalapril and metoprolol in
proteinuria in diabetic nephropathy. B M J. 1990;
300 : 904-7.
3. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H,
Aurell M. Beneficial effects of renal function in
patients with diabetic nephropathy. B M J 1986;
293 : 471-4.
4. Bolzano K, Arriaga J, Bernal R, Bernades H, Calderon
JL et al. The antihypertensive effect of lisinopril
compared to atenolol in patients with mild to moderate
hypertension. J Cardiovascular Pharmacology. 1987;
9 (Suppl-3) : 543-547.
5. Cheng JK, Ma JT, Chan MK. Comparison of captopril
and enalapril in the treatment of hypertension in
patients with non insulin dependent diabetes mellitus
and nephropathy. Int Urol Nephrol 1990;22:295-303.
6. Christiansen JS, Anderson AR, Koch Anderson J et al:
The natural history of diabetic nephropathy.
Diabetic Nephro 1985; 4 : 104-106.

7. Christiansen JS, Parving MH. The effect of short term strict metabolic control on albuminuria in insulin dependent diabetics with normal kidney function and diabetic nephropathy. *Diabetic Nephropathy*, 1984; 3 : 127-9.
8. Donohoe JE, Kelly J, Laher MS, Doyle GD. Lisinopril in the treatment of hypertensive patients with renal impairment. *Am J Med*, 1988; 85(Suppl,3B) : 31-34.
9. Dupont AG, Vander Niepen E, Volckaert A, Ingels M, Bossuyt AM et al. Improved renal function during chronic lisinopril treatment in moderate to severe primary hypertension. *J Cardiovascular Pharmacology*, 1987; 10 (Suppl, 7) : S148 - S150.
10. Friedmans, Iones HW III, Golbetz HV, Lee JA, Little HL, Nyers BD. Mechanisms of proteinuria in diabetic nephropathy II. *Diabetes*, 1983; 32(Suppl 2) : 40-46.
11. Heeg JE, De Jong PE, Hem GK, Zeeuw D. Reduction of proteinuria by angiotensin converting enzyme inhibition. *Kidney Int* 1987; 32 : 78-83.
12. Heel RC, Brogden RN, Speight TN, Avery GS. Captopril a preliminary review of its pharmacological properties and therapeutic efficacy. *Drugs*, 1980; 20: 469-52.
13. Hommel E, Parving HE, Mathiesen E, Edsberg G, Nielsen MD, Giese J. Effect of captopril on kidney function in insulin - dependent diabetic patients with nephropathy. *Br Med J Clin Res*, 1986; 292 : 467-70.

14. Hostetter HT, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. *N Engl J Med*, 1979; 300 : 638-41.
15. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. *Am J Med*, 1982; 72 : 375-80.
16. Jenkins AC, Dreslinski GR, Tardos SS, Groel JT, Fand R, Herczeg SA. Captopril in hypertension, seven years later. *J Cardiovas Pharmacol* 1983; 7 : 96-101.
17. Jhoannes FE, Mann Christine Reisch Eberhard Rita. Use of angiotensin converting enzyme for the preservation of kidney function. *Nephron*, 1990; 55 (Suppl-1) : 38-42.
18. Kibriya MG, Khan AR, Rashid HU et al. Effect of captopril and nifedipine on kidney function and proteinuria in non-insulin dependent diabetes (NIDDM) with nephropathy. Abstract of XI International Congress of Nephrology, Tokyo, Japan July 1990; 160 A : 15-20.
19. Magensen CE. Progression of nephropathy in long term diabetics with proteinuria and effect of initial antihypertensive treatment. *Scand J Clin Lab Invest*, 1977; 36 : 383-8.

20. Marre M, Leblanc II, Sunrez L, Gyenne TT, Menard J, Passa PH. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. *B M J*, 1987; 294 : 1448-52.
21. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients, with microalbuminuria. *B M J*, 1991; 303 : 81-87.
22. Mogensen E. Microalbuminuria as a predictor of clinical diabetic nephropathy. *Kidney Int*, 1987; 31 : 373-89.
23. Morelli E, Loon Meyer T, Peters W, Myers BD. Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. *Diabetes*, 1990; 39:76-82.
24. Mathiesen ER, Rann B, Jensen T, Storm B, Deckert T. The relationship between blood pressure and urinary albumin excretion in the development of microalbuminuria. *Diabetes*, 1990; 39 : 245-9.
25. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. *Lancet*, 1983; i : 1175-8.
26. Parving HH, Gall MA, Skott P, Jorgensen HE, Jorgensen F, Larsen S. Prevalence and causes of albuminuria in non-insulin dependent diabetic patients. *Kidney Int*, 1990; 37 : 243A.

27. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. *Br Med J Clin Res*, 1988; 297:1086-91.
28. Pedersen MM, Schmitz A, Pedersen EB, Daneilsen H. Christensen JS. Acute and long term renal effects of angiotensin converting enzyme inhibition in normotensive, non albuminuric insulin dependent diabetic patients. *Diabetic Me*, 1989;5 : 562-9.
29. SiPhae Lee, Tae Yong Kin, Jeong Sik Lim, Hong Khee Kim and Jae Woo Lee. Prospective study of effect of converting enzyme inhibitor, captopril on renal function and proteinuria in diabetic nephropathy. Abstract XIth International Congress of Nephrology, Tokyo Japan July, 1990; 12-20 : 160 A.
30. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. *Diabetes*, 1989;38:1077-81.
31. Struthers AD. The choice of antihypertensive therapy in the diabetic patients. *Postgrad Med, J*, 1985; 61 : 563-9.
32. Taguma Y, Kitamoto Y, Futaki G, Veda H, Monna H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y. Effect of captopril on heavy proteinuria in azotemic diabetics. *N Engl J Med* 1985; 313 : 1617-1620.

33. Veterans Administration cooperation study group on antihypertensive agents. Low dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med, 1984; 144 : 1947-53.
34. Yasuo-Veda Wataru Aoi, Shiro Yamachika, Takoo Shikaya. Beneficial effects of angiotensin converting enzyme inhibitor on renal function and glucose homeostatis in diabetic with hypertension. Nephron 1990; 55 (Suppl -1) : 85-98.
35. Zatz R, Meyer TW, Dunn BR et al. Lowering of arterial pressure (MAP) limits glomerular hypertension and albuminuria in experimental diabetes (Abstract) Kidney Int, 1985; 27 : 247.
36. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennka HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77 : 1925-1930.
